Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Vignetti

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 23, 2007
Use of interleukin-2 in the management of haematological malignancies: focus on minimal residual diseaseF Mandelli, S Capria, M Vignetti, et al.
La Pediatria Medica E Chirurgica : Medical and Surgical Pediatrics|May 1, 1984
[Assistance procedures in the perinatal period that condition breast feeding at the time of discharge from the hospital]A A Zuppa, M Vignetti, C Romagnoli, et al.
Haematologica|November 1, 1989
Flow cytometric measurement (H-1 Technicon) of microcytic and hyperchromic red cell populations in pediatric patients affected by hereditary spherocytosis (HS)P Ialongo, M Vignetti, G Cigliano, et al.
Studies in Health Technology and Informatics|February 24, 2001
Is workflow technology suitable to represent and manage clinical trials?P Fazi, P Grifoni, D Luzi, et al.
Haematologica|March 1, 1993
Haematological monitoring of acute lymphoblastic leukemia by automated flow cytochemistry (Bayer/Technicon H*1)P Ialongo, M C Lubrano, S Fenu, et al.
Haematologica|November 1, 1990
IL-2 in the treatment of chronic myeloid leukemia after lymphoid blast crisis: a pilot studyG Meloni, R Foà, S Tosti, et al.
Leukemia & Lymphoma|May 1, 1996
Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: updated experience with 20 casesG Meloni, M Vignetti, C Andrizzi, et al.
Stem Cells (Dayton, Ohio)|July 1, 1993
Interleukin 2 treatment in acute myelogenous leukemiaF Mandelli, M Vignetti, S Tosti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1992
Pretransplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: neurological and electroencephalographic prospective studyG Meloni, U Raucci, R M Pinto, et al.
Haematologica|July 1, 1996
Lack of efficacy of a double autograft program to prolong survival of chronic myelogenous leukemia patients in blastic transformationS Capria, M Vignetti, E Montefusco, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 23, 2007
Use of interleukin-2 in the management of haematological malignancies: focus on minimal residual diseaseF Mandelli, S Capria, M Vignetti, et al.
La Pediatria Medica E Chirurgica : Medical and Surgical Pediatrics|May 1, 1984
[Assistance procedures in the perinatal period that condition breast feeding at the time of discharge from the hospital]A A Zuppa, M Vignetti, C Romagnoli, et al.
Haematologica|November 1, 1989
Flow cytometric measurement (H-1 Technicon) of microcytic and hyperchromic red cell populations in pediatric patients affected by hereditary spherocytosis (HS)P Ialongo, M Vignetti, G Cigliano, et al.
Studies in Health Technology and Informatics|February 24, 2001
Is workflow technology suitable to represent and manage clinical trials?P Fazi, P Grifoni, D Luzi, et al.
Haematologica|March 1, 1993
Haematological monitoring of acute lymphoblastic leukemia by automated flow cytochemistry (Bayer/Technicon H*1)P Ialongo, M C Lubrano, S Fenu, et al.
Haematologica|November 1, 1990
IL-2 in the treatment of chronic myeloid leukemia after lymphoid blast crisis: a pilot studyG Meloni, R Foà, S Tosti, et al.
Leukemia & Lymphoma|May 1, 1996
Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: updated experience with 20 casesG Meloni, M Vignetti, C Andrizzi, et al.
Stem Cells (Dayton, Ohio)|July 1, 1993
Interleukin 2 treatment in acute myelogenous leukemiaF Mandelli, M Vignetti, S Tosti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1992
Pretransplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: neurological and electroencephalographic prospective studyG Meloni, U Raucci, R M Pinto, et al.
Haematologica|July 1, 1996
Lack of efficacy of a double autograft program to prolong survival of chronic myelogenous leukemia patients in blastic transformationS Capria, M Vignetti, E Montefusco, et al.
Pageof 5